In a recent Phase 2 study presented in June 2025, combining it with semaglutide (the active ingredient in Wegovy) led to remarkable outcomes for participants with obesity: An average weight loss of 22% over 72 weeks (compared to 16% with semaglutide alone) About 93% of that loss coming from fat mass, with minimal impact on lean muscle A 58% drop in visceral fat (versus 36% with semaglutide alone) All achieved without requiring dietary or exercise modifications This stands out because typical weight-loss drugs, like GLP-1 agonists, often result in losing both fat and musclea downside, since muscle boosts metabolism and supports overall health as we age
References Godlewska BR, Williams S, Emir UE, Chen C, Sharpley AL, Goncalves AJ, et al
These changes can make skin lesion assessment more difficult
A post-hoc analysis of SURMOUNT-5 data examined predicted 10-year cardiovascular disease risk using established risk calculators
This can be particularly detrimental when using semaglutide, as it is designed to help regulate your appetite and blood sugar levels